drugset / Trial / NCT04679350
Efficacy and Safety of hzVSFv13 in Patients With COVID-19 Pneumonia
RandomizedParallel-groupQuadruple-blindTreatment
Summary
To explore the efficacy and confirm the safety of the concomitant administration of the standard of care and hzVSF-v13 in patients with COVID-19 infection
Timeline
- Start
- 2021-03-18
- Primary completion
- 2022-11-30
- Completion
- 2022-12-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Burfiralimab | Monoclonal antibody | 50 mg | Intravenous |
| Subject | Burfiralimab | Monoclonal antibody | 200 mg | Intravenous |